Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1942 Added to Stable Antidepressant Therapy in Treatment-Resistant Depression
NCT04663321Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- May 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-1942 in treatment-resistant depression (TRD) (3 arms), sponsored by Merck & Co. Primary endpoints: Montgomery-Asberg Depression Rating Scale Total Score at 3 weeks, Adverse Events at 6 weeks and 1 more. Started May 2021; status: terminated.
02
Drugs
MK-1942
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04663321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04663321.